Granutec to sell private-label OTC naproxen in January once Aleve exclusivity expires.
This article was originally published in The Tan Sheet
Executive Summary
GRANUTEC PRIVATE-LABEL OTC NAPROXEN SODIUM is set to be introduced immediately following expiration of Aleve's market exclusivity on Jan. 11, 1997. Granutec's parent company, Novopharm, received tentative ANDA approval, pending expiration of the exclusivity period for OTC naproxen sodium 220 mg tablets and caplets, on August 20.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning